While most accidental overdoses can be managed with supportive care and monitoring, understanding the potential risks, recognizing warning signs, and knowing when to seek medical attention are essential for patient safety
Semaglutide (Wegovy) gained Part D coverage for beneficiaries with obesity and established cardiovascular disease or high cardiovascular risk, following the SELECT trial results
It contains active compounds like geniposide and gardenoside, which research has shown to influence GLP-1 signaling and metabolic health
They should be carefully administered to patients with risks of hypovolemia (older age, cardiovascular diseases, treatment with diuretics, liver cirrhosis with circulatory dysfunction)
Kidneys: Improves kidney function, reduces anemia risks, and prevents aspartame-related kidney diseases